SG11201405159WA - Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging - Google Patents

Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging

Info

Publication number
SG11201405159WA
SG11201405159WA SG11201405159WA SG11201405159WA SG11201405159WA SG 11201405159W A SG11201405159W A SG 11201405159WA SG 11201405159W A SG11201405159W A SG 11201405159WA SG 11201405159W A SG11201405159W A SG 11201405159WA SG 11201405159W A SG11201405159W A SG 11201405159WA
Authority
SG
Singapore
Prior art keywords
nanoparticles
imaging
preparation
drug delivery
targeted drug
Prior art date
Application number
SG11201405159WA
Inventor
Didier Bazile
Patrick Couvreur
Harivardhan Reddy Lakkireddy
Nicolas Mackiewicz
Julien Nicolas
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201405159WA publication Critical patent/SG11201405159WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6852—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
SG11201405159WA 2012-02-28 2013-02-28 Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging SG11201405159WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305236.7A EP2634179A1 (en) 2012-02-28 2012-02-28 Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging
PCT/EP2013/054085 WO2013127949A1 (en) 2012-02-28 2013-02-28 Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging

Publications (1)

Publication Number Publication Date
SG11201405159WA true SG11201405159WA (en) 2014-09-26

Family

ID=47757620

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405159WA SG11201405159WA (en) 2012-02-28 2013-02-28 Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging

Country Status (14)

Country Link
US (1) US9364444B2 (en)
EP (3) EP2634179A1 (en)
JP (1) JP6155287B2 (en)
KR (1) KR102052225B1 (en)
CN (1) CN104470904B (en)
AU (2) AU2013224926B2 (en)
CA (1) CA2864950C (en)
ES (2) ES2666243T3 (en)
IL (1) IL234342A (en)
MX (1) MX350589B (en)
PL (2) PL2820002T3 (en)
RU (1) RU2631653C2 (en)
SG (1) SG11201405159WA (en)
WO (1) WO2013127949A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10056907B1 (en) 2011-07-29 2018-08-21 Crossbar, Inc. Field programmable gate array utilizing two-terminal non-volatile memory
EP2827913B1 (en) * 2012-03-19 2020-09-02 Neomend, Inc. Co-precipitation method
CN103627386B (en) * 2013-12-04 2016-04-20 哈尔滨师范大学 A kind of preparation method of fluorogold nano-cluster of fluorescent probe folic acid functionalization
US9228044B2 (en) 2014-04-02 2016-01-05 International Business Machines Corporation Versatile, facile and scalable route to polylactic acid-backbone graft and bottlebrush copolymers
US9458268B2 (en) 2014-04-02 2016-10-04 International Business Machines Corporation Lactide-functionalized polymer
CN105111265B (en) * 2014-08-28 2018-04-06 成都先导药物开发有限公司 The method that one kind uses " one kettle way " mark modified biological macromolecular
US9505858B2 (en) 2014-10-21 2016-11-29 International Business Machines Corporation Polylactic acid (PLA) with low moisture vapor transmission rates by grafting through of hydrophobic polymers directly to PLA backbone
US9187597B1 (en) 2014-10-21 2015-11-17 International Business Machines Corporation Flame-retardant polylactic acid (PLA) by grafting through of phosphorus-containing polymers directly to PLA backbone
US9193818B1 (en) 2014-10-29 2015-11-24 International Business Machines Corporation Toughened polylactic acid (PLA) by grafting through of impact-modifying polymers directly to PLA backbone
KR102368068B1 (en) 2015-08-24 2022-02-25 삼성전자주식회사 Composition for manufacturing semiconductor device and method of manufacturing semiconductor device using the composition
US20190298855A1 (en) * 2015-11-20 2019-10-03 Cristal Delivery B.V. Nanoparticles with active targeting
EP3383315B1 (en) 2015-11-30 2023-09-27 Aleo BME, Inc. Polymeric materials for biomedical applications
KR101630397B1 (en) * 2015-12-31 2016-06-24 한국과학기술원 Composition for Phototherapy of Cancer Comprising Complex of Liposome, Indocyanine Green And Anti-cancer drug
WO2018071256A1 (en) * 2016-10-10 2018-04-19 University Of Massachusetts Ultralow-power near infrared lamp light operable targeted organic nanoparticle photodynamic therapy
CN108358995B (en) * 2017-01-25 2021-07-06 四川大学 CP-iRGD polypeptide, iDPP nanoparticle, drug-loaded compound and preparation method and application thereof
CN109010287A (en) * 2018-02-05 2018-12-18 上海交通大学医学院附属第九人民医院 Disease of inner ear diagnosis, prevention or therapeutic agent and preparation method thereof
CN109738387A (en) * 2018-12-29 2019-05-10 佛山科学技术学院 A kind of optical coherence chromatography imaging method and device green based on the indoles mountain valley with clumps of trees and bamboo
US11471412B1 (en) 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
CN110128665B (en) * 2019-05-13 2021-03-26 苏州大学 Amphiphilic block polymer near-infrared fluorescent probe based on azo reductase response and application
WO2020243697A1 (en) * 2019-05-31 2020-12-03 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
WO2021076952A1 (en) * 2019-10-16 2021-04-22 Board Of Regents, The University Of Texas System Target delivery of non-biologics through nanotechnology for tissue repair
CN111253556B (en) * 2020-03-20 2022-02-18 南京工业大学 Functionalized recyclable high-molecular homopolymer and preparation method and application thereof
CN111888333A (en) * 2020-08-11 2020-11-06 深圳大学 Transferrin receptor targeted nano micelle and preparation method and application thereof
WO2022063209A1 (en) * 2020-09-25 2022-03-31 亭创生物科技(上海)有限公司 Functionalized diblock copolymer, and preparation method therefor and use thereof
FI4103236T3 (en) 2020-10-27 2023-11-09 Elucida Oncology Inc Folate receptor targeted nanoparticle drug conjugates and uses thereof
KR102430034B1 (en) * 2021-02-18 2022-08-05 포항공과대학교 산학협력단 Nitric oxide sensitive hydrogel
CN112920396B (en) * 2021-02-26 2023-02-24 商丘师范学院 Synthesis method of hydroxyl-terminated high-oxygen-content high-flexibility azide polymer
CN114813998B (en) * 2022-03-24 2023-05-23 天津键凯科技有限公司 Polymer detection method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678168B1 (en) 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa NANOPARTICLES HAVING CAPTURE TIME BY THE EXTENDED RETICULO ENDOTHELIAL DYSTEM.
US5612052A (en) * 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2003093344A1 (en) * 2002-05-03 2003-11-13 Janssen Pharmaceutica N.V. Polymeric microemulsions
US8545830B2 (en) 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
US7371781B2 (en) 2003-09-22 2008-05-13 University Of Utah Research Foundation Tumor environment-induced ligand-expressing nanocarrier system
RU2326655C1 (en) * 2006-11-09 2008-06-20 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Method of incapsulation of protein bearing materials in microspheres from copolymer polylactide-polyglycolide
US9056129B2 (en) 2007-02-09 2015-06-16 Northeastern University Precision-guided nanoparticle systems for drug delivery
JP2011525180A (en) * 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド Method for the manufacture of targeted drugs functionalized with diblock copolymers for use in the production of therapeutically targeted nanoparticles
US20110177619A1 (en) * 2008-07-14 2011-07-21 Andrew Metters In vitro diagnostic markers comprising carbon nanoparticles and kits
JP5396180B2 (en) 2009-07-27 2014-01-22 東京エレクトロン株式会社 Selective oxidation treatment method, selective oxidation treatment apparatus, and computer-readable storage medium
US9181224B2 (en) * 2009-10-13 2015-11-10 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
US20110171248A1 (en) * 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
CA2798739A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
US20120064110A1 (en) * 2010-08-20 2012-03-15 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin

Also Published As

Publication number Publication date
WO2013127949A1 (en) 2013-09-06
JP2015513591A (en) 2015-05-14
AU2016269511B2 (en) 2018-04-19
RU2631653C2 (en) 2017-09-26
US20150037419A1 (en) 2015-02-05
ES2666243T3 (en) 2018-05-03
AU2013224926A1 (en) 2014-09-18
ES2583928T3 (en) 2016-09-22
IL234342A (en) 2017-01-31
RU2014139048A (en) 2016-04-20
EP3034498B1 (en) 2018-01-17
PL2820002T3 (en) 2016-10-31
CA2864950A1 (en) 2013-09-06
KR20140137389A (en) 2014-12-02
EP3034498A1 (en) 2016-06-22
CN104470904A (en) 2015-03-25
MX2014010390A (en) 2014-11-21
JP6155287B2 (en) 2017-06-28
CN104470904B (en) 2017-08-08
US9364444B2 (en) 2016-06-14
EP2820002A1 (en) 2015-01-07
CA2864950C (en) 2020-04-07
EP2634179A1 (en) 2013-09-04
EP2820002B1 (en) 2016-04-20
MX350589B (en) 2017-09-11
AU2016269511A1 (en) 2017-01-05
KR102052225B1 (en) 2019-12-04
PL3034498T3 (en) 2018-07-31
AU2013224926B2 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
SG11201405159WA (en) Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging
HK1213503A1 (en) Drug delivery medical device
HK1208387A1 (en) Drug delivery device
HK1208388A1 (en) Drug delivery device
HK1205928A1 (en) Ocular drug delivery system
HK1206655A1 (en) Drug delivery device
ZA201306464B (en) Nanoparticles delivery systems,preparation and uses thereof
SI3081249T1 (en) Drug delivery device
HK1206654A1 (en) Drug delivery device
EP2983659A4 (en) Drug delivery polymer and uses thereof
ZA201506530B (en) Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
HK1211249A1 (en) Device and methods for targeted tissue drug delivery
IL235163B (en) Medicament delivery device
HK1205702A1 (en) Drug delivery device
HK1202465A1 (en) Drug delivery device
HK1211246A1 (en) Drug delivery device
HK1211220A1 (en) A pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent
HK1205704A1 (en) Drug delivery device
EP2914247A4 (en) Drug delivery particle formulations with targeting moieties
EP2926811A4 (en) Artemether-containing pharmaceutical composition, preparation, and use thereof
EP2896401A4 (en) Targeted drug delivery system for poorly soluble drug
IL234887A0 (en) Cuff-shaped drug delivery device for the penis
EP2826492A4 (en) Drug delivery conjugate capable of controlled release, and use thereof
GB201223447D0 (en) Conjugate compounds for targeted drug deliver and uses thereof
PT2670394T (en) Nanoparticles delivery systems, preparation and uses thereof